Preliminary Results from CHALLENGE-MIG Trial Comparing Emgality vs Nurtec ODT for Episodic Migraine Prevention in Adults Reported

Preliminary results of the CHALLENGE-MIG clinical trial (NCT05127486) comparing Emgality (galcanezumab; Lilly, Indianapolis, IN) with Nurtec ODT (rimegepant orally disintegrating tablet; Biohaven, New Haven, CT) treatment for episodic migraine prevention in adults revealed thatEmgality did not meet the study's primary endpoint, defined as statistical superiority to Nurtec ODT on the percentage of participants achieving a 50% or greater reduction in monthly migraine headache days. The safety profiles of Emgality and Nurtec ODT were consistent with those previously reported.

The phase 4, double-blind, placebo-controlled study included data from 580 adult participants with diagnosis of migraine, with or without aura, as determined bystudy investigators in accordance with the International Headache Society International Classification of Headache Disorders, third edition. One treatment group received 4 subcutaneous injections of Emgality 120 mg (a loading dose of 2 injections followed by 2 additional monthly injections) and placebo ODT, and the other treatment group received 45 doses of Nurtec ODT 75 mg (1 tablet every other day) and placebo injection.

Commenting on the significance of the CHALLENGE-MIG results, Anne White, Executive Vice President of Eli Lilly and Company and President of Lilly Neuroscience, notes, "These results bolster our knowledge of Emgality's ability to work quickly and help patients improve their quality of life with less frequent dosing."  

Full results of the CHALLENGE-MIG clinical trial will be disclosed later this year.